Prot #1311.3: BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind Trial for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)

Project: Research project

Project Details

StatusFinished
Effective start/end date3/30/16 → 3/30/19

Funding

  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1311.3)